Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The ZEUS trial, officially titled “ZEUS – Effects of Ziltivekimab Versus P...

Novo Nordisk’s ZEUS Trial Reaches Completion: What It Could Mean for NVO Investors

The two companies dominate the market for obesity medications. 


Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements

The new medication helps people who also have diabetes and cardiovascular disease. 


Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The AMAZE 13 study, formally titled “Efficacy and Safety of Zenagamtide s....

Novo Nordisk’s AMAZE 13 Trial Adds Fresh Momentum to Its Obesity Pipeline

Novo Nordisk ( ($NVO) ) has shared an announcement. On 6 May 2026, Novo Nordisk A/S launched a share repurchase programme under EU Safe Harbour rul...

Novo Nordisk Ramps Up DKK 15 Billion Share Buyback Programme

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Novo Nordisk, with a price target of DKK290.00. Accor...

Novo Nordisk (0QIU) Receives a Hold from Deutsche Bank

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The phase 3 study “Efficacy and Safety of Co-administered Cagrilintide and...

Novo Nordisk’s CagriSema Trial Wraps Up: What Completed Phase 3 Data Could Mean for NVO

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S is running a large Phase 3 study called “Efficacy and Saf...

Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The Phase 2 study Efficacy and Safety of Once-weekly Subcutaneous UBT251 i...

Novo Nordisk’s New Diabetes Bet: What the UBT251 Trial Could Mean for NVO Investors

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK332.00. According to TipRan...

Novo Nordisk (0QIU) Receives a Hold from UBS

Novo Nordisk A/S ($NVO), a global healthcare company best known for its diabetes and obesity treatments, reported new phase 3 data that could stren...

Novo Nordisk’s Hemophilia Drug Delivers Strong Results, but Analysts See 10% Downside for NVO Stock

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk has withdrawn a Phase 2 study titled “A Phase 2 Study to Comp...

Novo Nordisk Halts Device Study for CagriSema: What It Means for NVO Investors

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. This placebo-controlled comparability study, officially titled “A Placebo-...

Novo Nordisk Withdraws CagriSema Device Study, Nudging Investor Focus Back to Core Obesity Assets

Hims & Hers Health ($HIMS) still has significant upside potential, but the risks are equally real. That is what makes the stock one of the more int...

Hims & Hers (HIMS) Stock Still Has Upside, but Risks Persist

Tech titan Microsoft ($MSFT) has launched a new $2.5 billion AI company parachuting its engineers into customers to help them drown out the noise o...

Microsoft Parachuting 6,000 AI Engineers into Global Clients as Part of New $2.5B AI Subsidiary

Novo Nordisk’s ($NVO) shares rose about 1% during Wednesday’s pre-market session as the U.S. Medicare health insurance program began covering obesi...

Novo Nordisk Stock (NVO) Rises as Medicare Starts Covering Obesity Drugs

HSBC Holdings ($HSBC) has been one of the best-performing big bank stocks in the world over the past year — up approximately 66% on a total return ...

You Bought HSBC for the Bank. Not the British Pound. Here’s the ETF That Keeps It That Way.

In a report released today, Michael Leuchten from Jefferies maintained a Hold rating on Novo Nordisk, with a price target of DKK285.00. According t...

Jefferies Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Novo Nordisk ( ($NVO) ) has shared an update. On 6 May 2026, Novo Nordisk launched a share repurchase programme under EU Safe Harbour rules as part...

Novo Nordisk Accelerates Share Buybacks Under DKK 15 Billion Programme

Analysts fell to the sidelines weighing in on Novo Nordisk (NVO) and Sanofi (SNY) with neutral ratings, indicating that the experts are neither bul...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$50.96	+2.60%	9.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$50.96	+2.6%	9.47M
3
4
5
6

NVO

NVO

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel